Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason E Chan

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Nature Cell Biology|June 15, 2026
Integrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolutionShiqi Diao, Jia Yi Zou, Shuo Wang, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Chemotherapy and COVID-19 Outcomes in Patients With CancerJustin Jee, Michael B Foote, Melissa Lumish, et al.
Cell|September 7, 2024
TGF-β and RAS jointly unmask primed enhancers to drive metastasisJun Ho Lee, Francisco J Sánchez-Rivera, Lan He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced SarcomaNicholas D Klemen, Sinchun Hwang, Martina Bradic, et al.
Journal for Immunotherapy of Cancer|April 2, 2022
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single centerEvan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Nature Cell Biology|June 15, 2026
Integrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolutionShiqi Diao, Jia Yi Zou, Shuo Wang, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Chemotherapy and COVID-19 Outcomes in Patients With CancerJustin Jee, Michael B Foote, Melissa Lumish, et al.
Cell|September 7, 2024
TGF-β and RAS jointly unmask primed enhancers to drive metastasisJun Ho Lee, Francisco J Sánchez-Rivera, Lan He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced SarcomaNicholas D Klemen, Sinchun Hwang, Martina Bradic, et al.
Journal for Immunotherapy of Cancer|April 2, 2022
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single centerEvan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, et al.
Journal for Immunotherapy of Cancer|September 5, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapyBenjamin A Nacev, Martina Bradic, Hyung Jun Woo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Pageof 3